London, UK, 4 February 2013: BTG plc (LSE: BTG), the specialist healthcare company, today
announces that a New Drug Application (NDA) seeking approval of Varisolve® (polidocanol
endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins has been submitted
to the US Food & Drug Administration (FDA). BTG expects to hear within Q2 2013 (calendar year) as
per the usual FDA timelines whether after initial review the submission has been accepted for full
review.
For further information contact:
BTG FTI Consulting
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605
Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000
Ben Atwell
+44 (0)20 7831 3113
About BTG
BTG is an international specialist healthcare company that is developing and commercialising products targeting
critical care, cancer and other disorders. The Group is seeking to acquire new products to develop and market
to specialist physicians, and is building a sustainable business financed by revenues from sales of its own
marketed products and from royalties and milestone payments on partnered products. For further information
about BTG please visit our website at www.btgplc.com.